- Patients
- Clinical Research
- Clinical trials
- KEYNOTE-057 Cohort C
2023-08-01T00:00:00.000+01:00
Ongoing
KEYNOTE-057 Cohort C
KEYNOTE-057 Cohort C
Bladder cancer
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) and Pembrolizumab in Combination with Other Investigational Agents in Subjects with High Risk Non-muscle-Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) and Pembrolizumab in Combination with Other Investigational Agents in Subjects with High Risk Non-muscle-Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy
Trial overview
Clinical Area
Medical Oncology
Disease / Condition
Bladder
Study Phase
II
Trial Identifiers
Registration number: NCT02625961. https://clinicaltrials.gov/study/NCT02625961
|